Market revenue in 2022 | USD 122.3 million |
Market revenue in 2030 | USD 183.9 million |
Growth rate | 5.2% (CAGR from 2022 to 2030) |
Largest segment | Meropenem |
Fastest growing segment | Meropenem |
Historical data covered | 2018 - 2021 |
Base year for estimation | 2022 |
Forecast period covered | 2023 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Meropenem, Imipenem, Ertapenem, Others Drug Class |
Key market players worldwide | Menarini Group, Pfizer Inc, Sun Pharmaceutical Industries, Lupin, Aurobindo Pharma, Merck & Co Inc, Venus Group |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to carbapenem market will help companies and investors design strategic landscapes.
Meropenem was the largest segment with a revenue share of 54.78% in 2022. Horizon Databook has segmented the Middle East & Africa carbapenem market based on meropenem, imipenem, ertapenem, others drug class covering the revenue growth of each sub-segment from 2018 to 2030.
Horizon Databook provides a detailed overview of continent-level data and insights on the Middle East & Africa carbapenem market, including forecasts for subscribers. This continent databook contains high-level insights into Middle East & Africa carbapenem market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account